This expansion of Vγ6+ and Vγ4+ cells conferred resistance to anti–PD-1 or anti–TIM-3 immunotherapy, as the absence of these cells in tumor-bearing mice resulted in sensitivity to T cell checkpoint inhibitors. The gene discussed is HAVCR2; the disease is neoplasm.